sfondo pallini

Innovation

into.blood

Developing

therapies.for

the.treatment

of.rare.diseases

Developing and commercializing specialized therapies for the treatment of rare diseases by using the patient’s own blood

Latest News

View all

EU support for Italian biotech’s red blood cell technology to treat ...

August 06, 2020

Read more

EryDel Announces Completion of Patient Enrollment in Phase 3 ATTeST Trial ...

April 14, 2020

Read more
img ufficio

Our Technology

EryDel’s proprietary platform technology is an easy to use, fast and automatic bedside procedure, to encapsulate small and large molecules including therapeutic enzymes in patients’ red blood cells. The cells are immediately re-infused into patients providing prolonged half-life in circulation, reduced immunogenicity, better tolerability and predictable vascular distribution.

Discover

A late Stage
and Broad Pipeline

Our People

About us
luca-benatti +

Luca Benatti
Chief Executive Officer

giovanni-mambrini +

Giovanni Mambrini
Chief Operating Officer

ronan-gannon +

Ronan Gannon
Chief Commercial Officer

alyssa-wyant +

Alyssa Wyant
Senior Vice President Regulatory Affairs

guenter-r-janhofer +

Guenter R. Janhofer
Chief Medical Officer